Jefferies maintains Accentia at hold

Accentia Biopharmaceuticals was maintained by Jefferies & Co., Inc. analyst Adam A. Walsh at a hold rating after the company reported its fourth-quarter earnings with Accentia's $2.04 loss per share beating Jefferies loss-per-share estimate of $2.14. Jefferies said it continues to believe SinuNase represents a $1 billion market opportunity, but before considering a more bullish stance, it is awaiting regulatory clarification. On Dec. 30, shares of the Tampa, Fla., biopharmaceutical company were down 2 cents, or 0.39%, at $5.05 on volume of 38,550 shares versus the three-month running average of 19,339 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.